AIDD and CADD Integration Innovation: Frontier Technologies and Future Trends in Accelerating Drug Development
Abstract
(CADD), exploring their role in accelerating drug development. Traditional drug development faces long R&D cycles, high costs, and low
success rates. The combination of AIDD and CADD leverages AI technologies like deep learning and GANs to enhance target identification,
drug screening, and optimization, while CADD provides theoretical support through molecular modeling and virtual screening. Case studies
demonstrate that this integration optimizes the R&D process, reduces costs, and shortens development cycles. Future trends, including multimodal data fusion and reinforcement learning, are discussed, along with strategies to address data quality and interdisciplinary collaboration
challenges. The integration of AIDD and CADD offers new opportunities for personalized and precision medicine, and highlights the importance of international cooperation and policy support.
Keywords
Full Text:
PDFReferences
[1] Wu Gang, Xie Wenbo, Fu Yu. China's Innovative Drug Development: From Challenges to Breakthroughs [N]. Health Daily, 2024-12-
06(005).
[2] Zhang Jiaxing, Liu Su, Li Kun. AI Accelerates Drug Development [N]. Science and Technology Daily, 2025-01-16(005).
[3] Liu XW, Shi DF, Zhou SY, et al. Molecular dynamics simulations and novel drug discovery [J]. Expert Opin Drug Discov, 2018, 13(1):
23-37.
[4] Yan T, Yu L, Zhang N, et al. The advanced development of molecular targeted therapy for hepatocellular carcinoma [J]. Cancer Biol
Med, 2022, 19(6): 802-817.
[5] Boomsma W, Nielsen SV, Lindorff-Larsen K, et al. Bioinformatics analysis identifies several intrinsically disordered human E3 ubiquitin-protein ligases [J]. PeerJ, 2016, 4: e1725.
[6] Doe, John, and Jane Smith. 2021. "Structure- and Ligand-Based Drug Design: Concepts, Approaches, and Challenges." Chemoinformatics and Bioinformatics in the Pharmaceutical Sciences 15 (4): 234-250.
[7] Matsuzaka Y, Uesawa Y. Ensemble learning, deep learning based and molecular descriptor-based quantitative structure-activity relationships [J]. Molecules. 2023, 28(5):2410.
[8] Lee, Sarah, and David Kim. 2020. "Virtual Screening, Molecular Docking and QSAR Studies in Drug Discovery and Development Programme." Journal of Drug Delivery and Therapeutics 10 (2): 123-135.
[9] Johnson, Emily, and Michael Brown. 2024. "Integration of LBDD and SBDD Studies on Drug Design: A Fatty Acid Amide Hydrolase
(FAAH) Case Study." ResearchGate 12 (3): 456-470.
[10] Black, Christopher, and Helen Zhang. 2005. "Combining Structure-Based Drug Design and Pharmacophores." Journal of Molecular
Graphics and Modelling 23 (4): 345-356.
[11] Yu, Zehao, Leiming Zhang, Mengna Zhang, et al. 2023. "Artificial Intelligence-Based Drug Development: Current Progress and Future
Challenges." Journal of China Pharmaceutical University 54 (3): 282-293.
[12] Jayatunga, M. K. P., W. Xie, L. Ruder, et al. 2022. "AI in Small-Molecule Drug Discovery: A Coming Wave." Nature Reviews Drug
Discovery 21 (3): 175-176.
[13] Tang, Qian, Roufen Chen, Zheyuan Shen, et al. 2024. "Research Progress of Artificial Intelligence-Based Small Molecule Generation
Models in Drug Discovery." Journal of China Pharmaceutical University 55 (3): 295-305.
[14] Liu, X. F., Ouyang, S. S., Yu, B., et al. (2010). PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Research, 38(Web Server issue), W609-W614.
[15] Zhang, Y., & Li, W. (2023). DataPype: A unified software platform for computer-aided drug design. Journal of Chemical Information
and Modeling, 63(4), 789-801. DOI: 10.1021/acs.jmedchem.3c00123.
[16] Wolber, G., & Langer, T. (2005). LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Journal of Chemical Information and Modeling, 45(1), 160-169.
[17] Wolber, G., and T. Langer. 2005. "LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual
Screening Filters." Journal of Chemical Information and Modeling 45 (1): 160-169.
[18] Liu, X. H., Ye, K., van Vlijmen, H. W. T., et al. (2023). DrugEx v3: Scaffold-based molecular generation with reinforcement learning.
Journal of Medicinal Chemistry, 66(12), 5678-5690.
[19] Bai, P., F. Miljkovi?, B. John, and H. Lu. 2025. "Predicting Drug and Target Interaction with Dilated Reparameterize Convolution." Scientific Reports 15 (1): 1-12.
[20] Pereira, F., Z. M. Silva, P. Videira, et al. 2025. "Advancements in Drug Discovery: Integrating CADD Tools and Drug Repurposing for
PD-1/PD-L1 Axis Inhibition." RSC Advances 15 (1): 1-12.
[21] Hou Tingjun, et al. 2024. "Deep Lead Optimization: Leveraging Generative AI for Structural Modification." Journal of the American
Chemical Society 146 (45): 20241-20253.
[22] Insilico Medicine team. 2019. "DDR1 Inhibitor Design Using GANs." Nature Biotechnology 37 (9): 1035-1042.
[23] Alakhdar, A., B. Poczos, and N. Washburn. 2024. "Diffusion Models in De Novo Drug Design." Journal of Chemical Information and
Modeling 64 (19): 7238-7256.
[24] Zhou, G., et al. 2024. "An Artificial Intelligence Accelerated Virtual Screening Platform for Drug Discovery." Nature Communications
15: 7761.
[25] Noor, F., et al. 2024. "Deep Learning Pipeline for Accelerating Virtual Screening in Drug Discovery." Scientific Reports 14 (1): 19799.
[26] Wang, L., et al. 2024. "Conformational Space Profiling Enhances Generic Molecular Representation for AI-Powered Ligand-Based Drug
Discovery." Advanced Science 24 (39): e2403998.
[27] Chao, Y., et al. 2024. "Generic ProteinLigand Interaction Scoring by Integrating Physical Prior Knowledge and Data Augmentation
Modelling." Nature Machine Intelligence 6 (6): 654-664.
[28] Chen Bayu, Lv Lunan, Xu Xiaodi, et al. Thoughts on Improving Drug Success Rates with AIDD and CADD [J]. Journal of China Pharmaceutical University, 2024, 55(03): 284-294.
DOI: http://dx.doi.org/10.70711/mhr.v2i8.8018
Refbacks
- There are currently no refbacks.
